{"id":212513,"name":"LILLY USA, LLC","slug":"lilly-usa-llc","state":"IN","country":"United States of America","description":"pharmaceuticals company","totalSpending":420000,"filings":8,"yearlySpending":[{"year":2021,"income":60000},{"year":2022,"income":240000},{"year":2023,"income":120000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["CROSSROADS STRATEGIES, LLC"],"lobbyists":["MATHEW LAPINSKI","JASON VAN PELT","SHAY HANCOCK","JASON GLEASON","BEN MCMAKIN","BRITTANY HERNANDEZ","CHRIS MILLER","HUNTER MOORHEAD","CHERYL JAEGER"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Issues related to the FDA's accelerated approval pathway. Issues related to Medicare beneficiary access to diagnostic radiopharmaceutical testing; Facilitating Innovative Nuclear Diagnostics Act of 20","Issues related to the FDA's accelerated approval pathway. Issues related to Medicare beneficiary access to diagnostic radiopharmaceutical testing; Facilitating Innovative Nuclear Diagnostics Act of 20","Issues related to the FDA's accelerated approval pathway.","Issues related to Medicare beneficiary access to diagnostic radiopharmaceutical testing; Facilitating Innovative Nuclear Diagnostics Act of 2021 (H.R.4479/S.2609).","Issues related to Medicare beneficiary access to diagnostic radiopharmaceutical testing; Facilitating Innovative Nuclear Diagnostics Act of 2021 (H.R.4479/S.2609); FY2023 Departments of Labor, Health "]}